Entity Details

Primary name HARS1_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP12081
EntryNameHARS1_HUMAN
FullNameHistidine--tRNA ligase, cytoplasmic
TaxID9606
Evidenceevidence at protein level
Length509
SequenceStatuscomplete
DateCreated1989-10-01
DateModified2021-06-02

Ontological Relatives

GenesHARS1

GO terms

Show/Hide Table
GOName
GO:0004821 histidine-tRNA ligase activity
GO:0005524 ATP binding
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005829 cytosol
GO:0006412 translation
GO:0006418 tRNA aminoacylation for protein translation
GO:0006427 histidyl-tRNA aminoacylation
GO:0032543 mitochondrial translation
GO:0042802 identical protein binding
GO:0042803 protein homodimerization activity

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm

Domains

Show/Hide Table
DomainNameCategoryType
IPR000738 WHEP-TRS domainDomainDomain
IPR004154 Anticodon-bindingDomainDomain
IPR004516 Histidine-tRNA ligase/ATP phosphoribosyltransferase regulatory subunitFamilyFamily
IPR006195 Aminoacyl-tRNA synthetase, class IIDomainDomain
IPR009068 S15/NS1, RNA-bindingFamilyHomologous superfamily
IPR015807 Histidine-tRNA ligaseFamilyFamily
IPR033656 Histidyl-anticodon-bindingDomainDomain
IPR036621 Anticodon-binding domain superfamilyFamilyHomologous superfamily
IPR041715 Class II Histidinyl-tRNA synthetase (HisRS)-like catalytic core domainDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616625 OMIMCharcot-Marie-Tooth disease 2W (CMT2W)An autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2W patients manifest a peripheral neuropathy mainly affecting the lower limbs and resulting in gait difficulties and distal sensory impairment. Most patients also have upper limb involvement. The disease is caused by variants affecting the gene represented in this entry.
614504 OMIMUsher syndrome 3B (USH3B)A syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00117 HistidineDrugbanksmall molecule